Johnson & Johnson (JNJ) has revealed that in the Phase 4 STAR study, TREMFYA successfully achieved both the primary and significant secondary endpoints, showing improvements in axial symptoms and a decrease in inflammation as assessed by MRI.

MoveSurge carries market-moving headlines the moment they reach the wire, each one with what the price did next.